GRYT Health and BMS Sign an Agreement to Launch Virtual Platform COVID Advocacy Exchange

 GRYT Health and BMS Sign an Agreement to Launch Virtual Platform COVID Advocacy Exchange

Bristol Myer Reports Results of Orencia (abatacept) in P-IV Early AMPLE Study for Moderate-to-Severe Rheumatoid Arthritis #EULAR2019

Shots:

  • COVID Advocacy Exchange is a virtual platform targeted to unite patient advocacy organizations, patients, policy makers, healthcare practitioners and industry in the exchange of information and will also provide data, including weekly live interactive sessions to foster discussion and collaboration
  • The platform will invite 100 global and local advocacy organizations and will provide access to data & information for offering support across therapy areas: oncology, cardiovascular, fibrosis, immunoscience, immunology, hematology, and multiple sclerosis
  • The companies collaborated for the virtual launch for co-creating a unique resource for aiding advocates in synchronizing, learning, & gathering resources including best practices. The expected launch date is May 18, 2020 with its first weekly live session available on www.covidadvocacyexchange.com

Click here to read full press release/ article | Ref: BMS | Image: Behance

Related News : BMS Expands its Existing Patient Support Programs to Aid Uninsured Patients in the US Amid COVID-19

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post